ADMA - ADMA Biologics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.3200
+0.1900 (+4.60%)
At close: 4:00PM EST

4.3800 +0.06 (1.39%)
Pre-Market: 8:56AM EST

Stock chart is not supported by your current browser
Previous Close4.1300
Open4.1700
Bid4.1600 x 2200
Ask12.8000 x 3100
Day's Range4.0700 - 4.3500
52 Week Range2.0800 - 6.3130
Volume834,541
Avg. Volume772,839
Market Cap256M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to.

  • GlobeNewswire

    ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA.

  • GlobeNewswire

    ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been accepted as a member of the Plasma Protein Therapeutics Association (PPTA) as a North America Member effective January 1, 2020. Adam Grossman, President and CEO of ADMA, will join the PPTA North America Board of Directors.

  • GlobeNewswire

    ADMA Biologics Named Company of the Year by BioFlorida

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.

  • GlobeNewswire

    ADMA Biologics Announces First Commercial Sales of ASCENIV™

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to.

  • GlobeNewswire

    ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV™ in the peer reviewed journal Immunotherapy.

  • GlobeNewswire

    ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Announces Poster Presentation at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that Adam Grossman, President and Chief Executive Officer, and Brian Lenz, Executive Vice President and Chief Financial Officer, are scheduled to present a corporate overview at the Cantor Global Healthcare Conference, to be held October 2-4, 2019, at the InterContinental New York Barclay, in New York City.  ADMA is scheduled to present on Wednesday, October 2, 2019 at 10:40 AM ET.

  • GlobeNewswire

    ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • GlobeNewswire

    ADMA Biologics to Present at Upcoming Investor Conferences

    Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, Fla., May 29, 2019 -- ADMA Biologics, Inc. (NASDAQ:.

  • GlobeNewswire

    ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

  • GlobeNewswire

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.

  • GlobeNewswire

    ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today that it has commenced a $45 million underwritten public offering of its common stock. The Company intends to grant the underwriter of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. Jefferies LLC is acting as sole book-running manager of the proposed offering.

  • GlobeNewswire

    FDA Approves Prior Approval Supplement for BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Reports First Quarter 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection.  The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin.

  • GlobeNewswire

    ADMA Receives Department of Health and Human Services U.S. License

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Department of Health and Human Services U.S. license No. 2019 to the Company in connection with the approval of ASCENIV™ Immune Globulin Intravenous, Human – slra 10% Liquid.

  • GlobeNewswire

    FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

    Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in Adults and Adolescents (12 to 17 Years of Age)FDA Approval Triggers Funding up.

  • GlobeNewswire

    ADMA Biologics Reports Full Year 2018 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.